A Selective Extracellular Matrix Proteomics Approach Identifies Fibronectin Proteolysis by A Disintegrin-like and Metalloprotease Domain with Thrombospondin Type 1 Motifs (ADAMTS16) and Its Impact on Spheroid Morphogenesis*

Rahel Schnellmann‡§¶**, Ragna Sack‡, Daniel Hess‡, Douglas S. Annis|, Deane F. Mosher||, Suneel S. Apte¶**, and Ruth Chiquet-Ehrismann†‡§

Secreted and cell-surface proteases are major mediators of extracellular matrix (ECM) turnover, but their mechanisms and regulatory impact are poorly understood. We developed a mass spectrometry approach using a cell-free ECM produced in vitro to identify fibronectin (FN) as a novel substrate of the secreted metalloprotease ADAMTS16. ADAMTS16 cleaves FN between its (I)5 and (I)6 modules, releasing the N-terminal 30 kDa heparin-binding domain essential for FN self-assembly. ADAMTS16 impairs FN fibrillogenesis as well as fibrillin-1 and tenascin-C assembly, thus inhibiting formation of a mature ECM by cultured fibroblasts. Furthermore ADAMTS16 has a marked morphogenetic impact on spheroid formation by renal tubule-derived MDCKI cells. The N-terminal FN domain released by ADAMTS16 up-regulates MMP3, which cleaves the (I)5-(I)6 linker of FN similar to ADAMTS16, therefore creating a proteolytic feed-forward mechanism. Thus, FN proteolysis not only regulates FN turnover, but also FN assembly, with potential long-term consequences for ECM assembly and morphogenesis. Molecular & Cellular Proteomics 17: 1410–1425, 2018. DOI: 10.1074/mcp. RA118.000676.

The extracellular matrix (ECM)1 is a network of proteins, glycoproteins and complex carbohydrates that normally undergoes continuous remodeling via coupled proteolytic degradation and biosynthesis. Deposition of a provisional ECM during morphogenesis, tissue regeneration or ECM assembly by cultured cells is known to rely heavily on the assembly of FN, an ECM glycoprotein, which is a crucial cell adhesion molecule and pro-migratory substrate (1, 2). Plasma and cellular FN are secreted as disulfide-bonded dimers that bind to cell surface integrins. Subsequently, cell contractility and centripetal integrin translocation expose cryptic binding sites in the FN dimers that allow their association and promote FN fibril assembly (1, 3). A major FN domain mediating initial self-assembly and promoting fibrillogenesis is the N-terminal heparin-binding domain spanning the first five type I repeats (4–7). The FN network serves as a template for the assembly of fibrillins, collagens, tenascin-C, latent TGFβ-binding proteins and other molecules and therefore has a crucial role in the formation of mature ECM (8–11). Consistent with the observed significant impact on ECM ontogeny, cell adhesion and migration in vitro, inactivation of the Fn1 gene in mice leads to embryonic lethality by 8.5 days of gestation, with embryos showing impaired cardiovascular development and other morphogenetic defects (12).

Whereas initiation of FN fibril assembly has been extensively investigated, mechanisms regulating fibril turnover and maturation, are poorly understood (1, 13). Even though a number of proteases are known to cleave FN (4, 13–17) little is known about how they affect FN networks and so far, the relationship between FN proteolysis and assembly has not been specifically investigated. The ADAMTS (a disintegrin-like and metalloproteinase domain with thrombospondin type I motif) family includes 19 secreted proteases, most of which act on ECM and are crucial regulators of morphogenesis (18, 19). ADAMTS16 is a poorly characterized family member without a known substrate, although it was reported to play a role during renal and gonadal development. Homozygous Adamts16 knockout male rats are infertile,
with reduced testicular size and cryptorchidism (20) and ADAMTS16 was linked to branching morphogenesis during renal development (21). In addition to its role during embryogenesis, ADAMTS16 was implicated in blood pressure regulation in rats and humans (22, 23) and linked to ovarian cancer and esophageal squamous cell carcinoma (24, 25). Thus, ADAMTS16 is well-connected to morphogenesis and human diseases, but without knowledge of its underlying mechanisms, i.e. its molecular characteristics, substrates, and the molecular pathways in which it participates.

Here, we identified FN as an ADAMTS16 substrate via a novel mass spectrometry (MS) approach, using a decellularized ECM produced in vitro by fibroblasts for substrate discovery. We show that ADAMTS16 cleaves FN near its N terminus with an immediate and long-term impact on ECM assembly. By upregulating MMP3 in the epithelial cell line MDCKI, ADAMTS16 creates an intriguing dual protease feed-forward loop that may serve to limit and fine-tune FN assembly and control tubular morphogenesis.

**EXPERIMENTAL PROCEDURES**

**Antibodies**—All antibodies and used dilutions are listed in supplemental Table S1.

**Expression Plasmids**—Mouse *Adamts16* cDNA clone (with sequence NM_172053) was purchased from Creative Biogene (Shirley, NY). All constructs were generated by PCR using this clone as a template and HiFidelity Polymerase (Qiagen, Hombrechtikon, Switzerland) following the manufacturer’s protocol. All constructs were C-terminally myc_His6 tagged and cloned into pCPE_pu (Invitrogen, Carlsbad, CA) for expression and verified by Sanger sequencing. ADAMTS16 mutant constructs were obtained by site directed mutagenesis PCR following a previously published protocol (26). For cloning and mutagenesis primer sequences see supplemental Table S2.

**Cell Culture**—HEK293-EBNA (CRL-10852, ATCC, Manassas, VA) cells were grown in DMEM supplemented with 10% FBS. To generate HEK293-EBNA cells stably expressing mouse ADAMTS16, mouse ADAMTS16-sh, mouse ADAMTS16-EA, or mouse ADAMTS16-sh-EA, cells were seeded on 0.1% gelatin-coated dishes (0.1% gelatin in MEM, supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin) and allowed to attach for 24 h. After 24 h the medium was replaced with fresh culture medium containing 10% FBS and 50 μM Tris-HCl (pH 7.5) for 14 days. Mouse BALB/c 3T3 fibroblasts (CCL-163, ATCC), human dermal fibroblasts (HDF, ATCC) and LN229 cells (CRL-2611, ATCC) were grown in DMEM supplemented with 10% FBS. MDCK strain I (MDCKI) cells, kindly provided by Dr. Martin Spiess (Basel, Switzerland), were grown in α-MEM supplemented with 10% FBS. To obtain MDCKI cells stably expressing mouse ADAMTS16, mouse ADAMTS16-sh, mouse ADAMTS16-EA, or mouse ADAMTS16-sh-EA, cells were transfected using FuGENE® 6 (Roche, Basel, Switzerland) and selected with puromycin for 14 days. All cell lines used in the experiments were tested for mycoplasma contamination by MycoAlert™ Mycoplasma Detection Kit (LT07–218, Lonza Basel, Switzerland).

**Western Blotting**—Cell extracts and conditioned media were prepared in Laemmli loading buffer with or without 2-mercaptoethanol and separated by SDS-PAGE. Proteins were transferred to PVDF membranes (Immobilon FL for fluorescence detection, EMD Millipore, Billerica, MA) and probed with primary antibody (supplemental Table S1) and detected by an enhanced fluorescence technique using an Odyssey CLx scanner (LI-COR Biosciences, Lincoln, NE).

**Protein Purification**—1 L of conditioned medium was filtered through a 0.22 μm filter (Corning, Corning, NY). After filtration the solution was applied to a pre-equilibrated 1 ml IMAC column (Ni-NTA agarose, Qiagen, Hombrechtikon, Switzerland) at 4 °C. Bound protein was eluted with 250 mM imidazole in 50 mM Tris-buffer (pH 7.5). For removal of imidazole, the protein solution was dialyzed against TBS (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) supplemented with 5 μM ZnCl2. Protein concentration was determined with a NanoDrop ND-1000 spectrometer (ThermoFisher Scientific, Reinach, Switzerland). Protein absorption coefficients were calculated using the PDB Protein Data Bank Param tool. The protein solution was stored in 50% (v/v) glycerol at −20 °C.

**Immunofluorescence**—HEK293-EBNA cells were seeded on 8-well glass chamber slides (Falcon Culture Slides, Thermo Fisher Scientific) and cultured in DMEM containing 10% FBS until they reached 80% confluence. Cells were transiently transfected with ADAMTS16-sh and ADAMTS16-CT, ADAMTS16 or empty vector only using Lipofectamine 3000 (Invitrogen/Life Technologies, CA). After 48 h under serum-free conditions the cells were fixed with 4% formaldehyde (PFA) for 20 min. The samples were incubated with anti-myc and anti-laminin for 1 h at room temperature, followed by incubation with Alexa conjugated secondary antibody. Samples were mounted in ProLong Gold with DAPI (Life Technologies) and imaged with a Leica TCS5 SPII confocal microscope. Images comparing conditions were acquired under identical camera settings and analyzed using ImageJ software (U. S. National Institutes of Health, Bethesda, Maryland). LN229 cells were seeded on 8 well glass chamber slides and cultured in DMEM containing 10% FBS until they reached 90% confluence. Cells were transiently transfected using Lipofectamine 3000. Cells were maintained in DMEM with 10% FBS for another 48 h before fixation and staining.

**Preparation of Cell-free ECM from HEK-EBNA Cells**—HEK-EBNA cells were transiently transfected and cultured for 48 h in DMEM/10% FBS. Cells were removed using extraction buffer (0.5% Na-deoxycholate, 10 mM Tris-HCL, pH 7.5) supplemented with protease inhibitor (Complete™, Mini Protease Inhibitor Mixture, Sigma-Aldrich) for 30 min at 4 °C. ECM was washed with 2 mM Tris-HCI (pH 7.5). Total protein was analyzed by SDS-PAGE under reducing conditions.

**Preparation of ECM Produced by Cultured BALB/c 3T3 Fibroblasts**—BALB/c 3T3 fibroblasts were cultured in DMEM supplemented with 10% FBS for preparation of cell-free ECM as previously described (27). Briefly, 1 × 106 fibroblasts were seeded on a 6 cm culture dish (Corning) precoated with 0.1% gelatin and allowed to attach for 24 h. After 24 h the medium was replaced with fresh culture medium containing 10% FBS and 50 μg/ml ascorbic acid (Merck Millipore, Darmstadt, Germany). The medium was replaced every 24 h for 5 days. The cells were extracted from the matrix using PBS containing 0.5% Triton X-100 and NH4OH. PBS was added to dilute the cellular debris and the plate was stored overnight at 4 °C. Debris were removed, and ECM was washed with cold PBS. 5 × 106 HEK cells stably expressing mouse ADAMTS16, mouse ADAMTS16-sh, mouse ADAMTS16-sh-EA or transfected with empty vector as a control, were seeded on this matrix and cultured for 24 h in serum-free medium. ADAMTS16-sh-EA served as the control for both wt-
Fibronectin Cleavage by ADAMTS16

ADAMTS16 and ADAMTS16-sh. The conditioned medium was analyzed by LC-MS/MS.

Sample Preparation and Analysis of the Digested ECM by Mass Spectrometry—The proteins in the medium were precipitated using trichloroacetic acid (TCA), washed with HPLC grade ice-cold acetone and dissolved in 0.5 M Tris pH 8.6 containing 6 M guanidine hydrochloride and aliquoted into four fractions for treatment with the endopeptidase Lys-C (Wako, Neuss, Germany) or trypsin (sequencing grade modified, Promega, Dübendorf, Switzerland). Asp-N (Roche) and combinations thereof after reduction with TCEP and alkylation with iodoacetamide (both Fluka, Buchs, Switzerland) and further addition of digestion buffer (50 mM Tris/HCl pH 8.6, 5 mM CaCl₂). Peptides were separated on an EASY n-LC 1000 liquid chromatography system equipped with a C18 Acclaim PepMap 100 trap-column (75 μm × 2 cm, 3 μm, 100 Å) and a C18 New Objective analytical column (75 μm × 25 cm, Reprosil, 3 μm) coupled to a Thermo Orbitrap Fusion mass spectrometer (Thermo Scientific) equipped with a New Objective Digital Pico View source. Data were collected over a 30 min linear gradient from 2% buffer B (0.1% formic acid in acetonitrile) to 25% buffer B, followed by a 5 min linear gradient from 25% to 40% buffer B. Buffer A contained 0.1% formic acid in water. Sample digests were acidified with trifluoroacetic acid ( Pierce) to a final concentration of 0.1% TFA.

Analysis and Peptide Identification by LC-MS/MS—Peptides were identified by searching SwissProt restricted to mammalian proteins (version 2015–01, # of entries searched for: 16920 mouse proteins) using Mascot Distiller (version 2.5.1, Matrix Science) and Mascot (version 2.5.1, Matrix Science) allowing the following post-translational modifications; fixed modifications: Carbamidomethyl (C), variable modifications: acetylation at protein N termini, deamidation at asparagine and glutamine, oxidation at methionine and phosphorylation at serine/threonine and no enzyme specificity. The number of max. missed cleavages was set to 1, with a peptide mass tolerance ± 10 ppm and a fragment mass tolerance ± 0.6 Da. Data were compiled and evaluated with Scaffold (version Scaffold_4.4.1.1; Proteome Software), considering proteins identified with at least five peptides and having thresholds for protein and peptides of 90%, with peptide FDR 2.1% (Prophet) and protein FDR 0% (Prophet). The FDR was calculated using Scaffold software using the following parameters: Protein Grouping Strategy: Experiment-wide grouping with binary peptide-protein weights. Peptide Thresholds: 90.0% minimum and Protein Thresholds: 90.0% minimum and 5 peptides minimum. Scaffold software was used for a qualitative analysis of ADAMTS16 cleavage products. For a quantitative analysis of single peptides, the area under the curves of the MS1 spectra of single peptides was analyzed using a label free approach. For this, the corresponding data files were loaded into Progenesis QI for proteomics (version 2.0.5556.29015, Waters). All raw data files of the single runs, a Scaffold file (.sfs) as well as the Mascot peak list (mgf files) and the corresponding search files (xml files) for the Progenesis QI quantification are available via ProteomeXchange with identifier PXD007284. 

In Vitro Fibrillogenesis—HDF and HEK293 cells were co-cultured in a 3:5 (fibroblasts: HEK cells) ratio in DMEM containing 10% FBS for 24 h, 48 h, or 4 days respectively. For 8-day co-cultures the cells were seeded in a 4:1 (fibroblasts: HEK cells) ratio. Cells were fixed in 4% PFA, stained and imaged using a Leica TCSS SPlI confocal microscope. Images were analyzed using ImageJ software.

3D-culture Staining and Imaging—MDCK cells were embedded in 3D collagen gels. Acid-solubilized collagen (Corning Collagen I) was mixed with 10X PBS in a 1:1 ratio, followed by pH adjustment to 7.5 with 0.1 M NaOH. The collagen concentration was adjusted to a final concentration of 2.5 mg/ml using α-MEM/10%FBS. 150 μl of collagen containing 1.5 × 10⁶ cells was poured into each well of an 8-well glass chamber slide and allowed to solidify at 37 °C. After gelation α-MEM containing 10% FBS was added and replaced every 24 h.

After 4 days or 8 days of culture, the 3D gels were fixed using 4% PFA for 30 min and permeabilized 3X 15 min at room temperature using 0.3% Triton X-100 in PBS. Primary antibodies were diluted in PBST and applied overnight at 4 °C. Gels were washed with PBST and incubated with secondary antibodies in PBST for 2 h at room temperature. Images were taken with a Leica TCSS SPlI confocal microscope and analyzed with ImageJ software.

RNA Analysis by qRT-PCR—Total RNA was isolated using the RNeasy Plus Micro Kit (Quiagen). RNA was reversed transcribed and relative mRNA levels were detected as described (28). Relative mRNA levels for the genes, normalized to TBP, were measured using Platinum® SYBR® Green qPCR SuperMix-UDG with ROX (Invitrogen). Real-time PCR was performed in a StepOnePlus Real-Time PCR System (Applied Biosystems, Rotkreuz, Switzerland) using a standard cycling profile. All samples were run in triplicates. Data were analyzed by the ΔΔCt method (29). RT-PCR primers are listed in supplemental Table S3.

Labeling of FN—0.5 mg of plasma FN (F0895, Sigma-Aldrich) was labeled using the Alexa Fluor 488 protein labeling kit (A10235,
Thermo Fisher Scientific) following the manufacturer’s instructions. 30 μg/ml of the labeled FN were plated on 8-well glass chamber slides. HEK-EBNA cells stably expressing wtADAMTS16, ADAMTS16-EA or empty vector were seeded under serum-free conditions and allowed to attach for 48 h prior to fixation and phalloidin staining.

**FN Cleavage**—Purified ADAMTS16-sh was incubated with plasma FN (Sigma-Aldrich) or 500 ng of the 70 kDa N-terminal FN fragment or the 4F1–2F2 produced in insect cells (30) for 4 h at 37 °C in TBS (pH 7.5) supplemented with 10 mM CaCl2. Cleavage products were analyzed by immunoblotting under reducing conditions.

**Experimental Design and Statistical Rational**—All grouped data are means ± S.E. The statistical analysis was performed using GraphPad InStat version 3.05. Differences between two groups were evaluated using a two-tailed Student t test for parametric data. Values of $p < 0.05$ were considered statistically significant. Empty vector and an inactive mutant of ADAMTS16 were used as control for all experiments. All qRT-PCR experiments were done in triplicates. Relative amount of FN was quantified using ImageJ software. Each condition was done in triplicate and a total of 12 images per condition were analyzed. For spheroid size quantification a total number of 50 spheroids per condition from three independent experiments together were evaluated. For lumen quantification a total of 16 spheroids per condition from 3 independent experiments were quantified.

Human FN digestion was done in biological triplicates and all triplicates were analyzed by LC-MS/MS to get statistically relevant quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouse FN peptide from decellularized ECM was verified in two quantifications of the cleavage peptides. The presence of the identified mouseFN peptide 270CERHALQSASAGSGS285 (GenBank ID NP_
ADAMTS16/ADAMTS16-EA

ADAMTS16-sh/ADAMTS16-sh-EA

ADAMTS16-TS6/ADAMTS16-TS6-EA

Signal peptide
Propeptide
Catalytic domain
Disintegrin-like domain
Cys-rich domain
Spacer domain
Thrombospondin type-1 repeat
PLAC domain
Myc/His6-tag
Furin cleavage site
Active site mutation E432A (EA)
Site of C-terminal processing

Fig. 1. ADAMTS16 binds ECM and is C-terminally processed. A. Domain organization of ADAMTS16 constructs. B. Western blot analysis of conditioned medium from HEK293-EBNA cells transfected with the indicated constructs or empty vector (v) using anti-myc antibody and enhanced chemiluminescence. The black arrowheads and asterisk indicate autocatalytic and non-autocatalytic C-terminal fragments of ADAMTS16 respectively. C. Western blot analysis of HEK293-EBNA cell lysate transfected with the indicated constructs or empty vector (v). The asterisks indicate autocalytic and non-autocatalytic C-terminal fragments of ADAMTS16. Z and M indicate the zymogen and mature forms arising from furin processing. D. Western blot analysis of cell-free ECM from HEK293-EBNA cells expressing various ADAMTS16 constructs or transfected with empty vector (v). The asterisks indicate C-terminal fragments. Z and M indicate the zymogen and mature forms arising from furin processing. E. HEK293-EBNA monolayers were stained for wtADAMTS16, ADAMTS16-CT and ADAMTS16-sh with anti-myc (red) and laminin (green) as ECM marker. The images show stronger localization of ADAMTS16-CT to the cell layer than ADAMTS16-sh. White arrows indicate co-localization of ADAMTS16 and laminin. The scale bar is 50 μm. The right-hand panels are 2X amplification of the boxed areas in the left-hand column.
Fig. 2. Identification and validation of FN as an ADAMTS16 substrate. A, Schematic of the proteomic strategy used to identify ADAMTS16 substrates. B, MS2 spectrum of the doubly charged FN peptide CERHALQSASAGSGS identified in the LysC-AspN digest of wtADAMTS16. C, Histogram of log10 ratios of relative abundance of the FN peptide CERHALQSASAGSGS identified by LC-MS/MS in the LysC/AspN digest showing its presence exclusively in matrix incubated with active ADAMTS16 and ADAMTS16-sh expressing cells, but not in the control samples. Log10 ratios compare wtADAMTS16 with ADAMTS16-sh-EA, ADAMTS16-sh with ADAMTS16-sh-EA and vector with ADAMTS16-sh-EA. Average of log10 ratios of all identified FN peptides, showed similar values between the samples, indicating equal amounts of FN in each sample. D, Domain structure of FN with expanded view of the amino acid sequence of the linker between domains (I)5 and (I)6 showing the peptide identified by LC-MS/MS (yellow highlight) and the potential ADAMTS16 cleavage site. E, The domain structure of FN and the N-terminal 70 kDa FN fragment (FN70K). Antibody binding sites of the monoclonal anti FN-NT (MAB1936) and the polyclonal anti-FN (Ruth Fibronectin Cleavage by ADAMTS16

Molecular & Cellular Proteomics 17.7

1415
Fibronectin Cleavage by ADAMTS16

034363) exclusively in digests of ECM by the two active ADAMTS16 constructs but not the catalytically inactive mutant and/or the vector control (Fig. 2B, 2C, supplemental Fig. S2A). The presence of the FN peptide \( ^{270\text{C}}\text{CERHTSVQTGSGS}^{285} \) was found in both active samples (wt-ADAMTS16 and ADAMTS16-sh) using LysC alone as working protease or LysC in combination with AspN (Table I, supplemental Table S5–S7). The findings could be reproduced in a second independent experiment (data available in ProteomeXchange with identifier PXD007284). This finding suggests that ADAMTS16 cleaves FN within its N-terminal linker sequence between domain (I)\(_9\) and (I)\(_9\) (Fig. 2C). We identified additional peptides showing cleavage sites that did not arise from the sample preparation process (Table I). Because these peptides were also identified in the control samples, but at lower abundance, we conclude that they were not uniquely targeted by ADAMTS16 and were not pursued further (Table I, II, supplemental Table S5, S7, supplemental Fig. S2C, S2D). The similar results obtained for wtADAMTS16 and ADAMTS16-sh indicate that although C-terminal processing influences enzyme localization, it does not significantly influence FN recognition and proteolysis. Although a unique peptide identified FN as a potential substrate of ADAMTS16, the FN sequence coverage did not vary between the different samples, indicating the same overall amount of FN in the conditioned medium (Fig. 2C, supplemental Fig. S2C, supplemental Table S7). On the other hand, differential sequence coverage was noted for biglycan, plectin, and serpinH1, but no unique peptides arising from ADAMTS16 cleavage were identified (Table II, supplemental Table S7). These molecules could also be potential ADAMTS16 substrates where unique cleaved peptides were not detected by LC-MS/MS.

For further validation of FN as substrate of ADAMTS16, cell culture dishes were coated with human plasma FN and cells stably expressing different ADAMTS16 constructs were seeded under serum-free conditions. ADAMTS16-mediated FN proteolysis was allowed for 24 h. The conditioned medium was analyzed for FN cleavage products by Western blotting using an antibody specific to the N-terminal domain of human FN. Samples incubated with ADAMTS16-sh showed a strong increase of the 30 kDa FN N-terminal heparin binding domain after 24 h of incubation in the conditioned medium compared with inactive mutant and vector control (supplemental Fig. S3A). To further validate FN as a substrate the conditioned medium was analyzed by mass spectrometry for specific FN cleavage peptides after 24 h of incubation with ADAMTS16-sh. The specific cleavage peptides \( ^{270\text{C}}\text{CERHTSVQTGSGS-GPFDVRRA}^{282} \) from the (I)\(_9\)-(I)\(_9\) linker sequence of FN was identified in very high abundance in the active ADAMTS16-sh sample but not in the inactive ADAMTS16-sh-EA and vector control samples, although overall FN peptide abundance was comparable supplemental Fig. S3B–S3D; supplemental Table S8, S9). This finding further suggests that ADAMTS16 cleaves FN within the N-terminal (I)\(_9\)-(I)\(_9\) linker. We identified additional human FN cleavage peptides toward the C-terminal side of this cleavage indicating that ADAMTS16 might cleave FN elsewhere in addition to the characterized N-terminal cleavage site (supplemental Table S8).

Because of the extensive post-secretion processing, purification of full-length ADAMTS16 was not feasible using the C-terminal tags, but ADAMTS16-sh was purified and its proteolytic activity was demonstrated by cleavage of the generic protease substrate \( \alpha2\)-macroglobulin (supplemental Fig. S4A) as previously demonstrated (32). To obtain biochemical validation that fibronectin is a substrate of ADAMTS16 and to determine the requirements for proteolysis, we incubated purified ADAMTS16-sh with different FN constructs. A recombinant 70 kDa FN fragment extending from module (I)\(_1\) to module (I)\(_9\) was cleaved to generate a 30 kDa N-terminal fragment (Fig. 2E, 2F). Full-length plasma FN, whose globular structure potentially masks susceptible peptide bonds, was not cleaved by purified ADAMTS16-sh in vitro (supplemental Fig. S4B). ADAMTS16-sh failed to cleave the linker of a shorter recombinant FN fragment spanning the (I)\(_9\) to (II)\(_9\) modules suggesting that binding of ADAMTS16 to FN may occur via domains distant from the cleavage site (Fig. S4C, S4D). We also tested the ability of wtADAMTS16 to cleave FN using a cell-based approach. Seeding of HEK-EBNA cells expressing wtADAMTS16, but not ADAMTS16-EA on Alexa488 labeled FN showed a loss of FN fluorescence underlying the cells (supplemental Fig. S4E), suggesting that in contrast to plasma FN in solution, bound plasma FN could be cleaved by ADAMTS16-expressing cells. In transiently transfected LN-229 glioblastoma cells, ADAMTS16 co-localized with FN fibrils in vitro (Fig. 2G) and the FN network was reduced in cells expressing wtADAMTS16 (supplemental Fig. S4F). Together, these findings indicate that FN is directly cleaved by ADAMTS16, but that cleavage requires a distant binding region on FN and exposure of the scissile bond by traction provided by cell contraction.

ADAMTS16 Inhibits FN Assembly and Elaboration of a Mature FN-dependent ECM—The 30 kDa N-terminal heparin

Chiquet) are indicated above full-length FN. F, Western blot analysis of FN70K incubated with purified active ADAMTS16-sh in the presence or absence of EDTA. Anti-FN antibody (MAB1936) specific to the N-terminal heparin-binding domain of FN was used to identify release of the 30 kDa N-terminal heparin-binding domain (black arrow). G, Co-localization of ADAMTS16 with FN fibrils. Transiently transfected LN229 cells were cultured for 48 h and stained for ADAMTS16-EA and ADAMTS16-sh-EA with anti-myc (red) and FN (green). The images show co-localization of ADAMTS16-EA and ADAMTS16-sh-EA with FN fibers, indicating that the C terminus of ADAMTS16 is not essential for FN binding. White arrows show co-localization of ADAMTS16 with FN. Scale bar is 50 μm. Lower panels show 2× amplification of the boxed areas in the top row.
### TABLE I

**Peptides and peptide ratios obtained from ADAMTS16 digestion of BALB/c 3T3 extracellular matrix**

| Protein name | Preceding amino acid | Peptide seq. | Succeeding amino acid | Precursor charge | mass/charge (m/z) | Working protease | log10 wtADAMTS16/ADAMTS16-sh-EA | log10 ADAMTS16-sh/ADAMTS16-sh-EA | log10 vector/ADAMTS16-sh-EA |
|--------------|----------------------|--------------|-----------------------|------------------|------------------|-----------------|-----------------------------|-------------------------------|----------------------------|
| FN           | K                    | 271CERHALQSASAGGS285 | F                     | 2+               | 759.34           | LysC/AspN       | 2.33                        | 3.29                          | -0.01                       |
| FN           | K                    | 271CERHALQSASAGGS285 | F                     | 2+               | 759.34           | LysC            | 3.51                        | 4.50                          | 1.66                        |
| FN           | K                    | 271CERHALQSASAGGS285 | F                     | 3+               | 506.56           | LysC            | 3.42                        | 4.29                          | 1.66                        |
| FN           | D                    | 565PIQCDQDSETRE267 | T                     | 2+               | 674.79           | LysC/Trypsin    | 0.65                        | 0.37                          | 0.15                        |
| LTBP-1       | Y                    | 158GDRALDFSEGYPETDPYFIQDR1604 | F | 3+       | 940.10           | LysC/Trypsin    | 0.62                        | 0.32                          | 0.07                        |
| POSTN        | T                    | 601LLVNELK610 | S                     | 2+               | 415.25           | LysC            | 0.2                         | 0.14                          | -0.08                       |
| GELS         | R                    | 459EGSNKVPDPATY463 | G                     | 2+               | 745.38           | AspN/Trypsin    | 0.37                        | -0.01                         | 0.18                        |

Comparison of peptides released from digests of decellularized BALB/c 3T3 ECM (mouse) with HEK-EBNA cells stably expressing wtADAMTS16, ADAMTS16-sh-EA, ADAMTS16-sh, and vector control as indicated in column headings. Peptides arising from cleavage by proteases different from the ones used for sample preparation (working proteases) are shown. No change in peptide abundance gives a ratio near 0. Increased peptide abundance in active samples gives a ratio >0. Ratios were calculated using Progenesis QI software.

All peptides shown in the table are of murine (BALB/c 3T3) origin.

All Mascot peak lists and search files used to quantify peptide ratios and abundance are available via ProteomeXchange with identifier PXD007284.

### TABLE II

**Unique peptide count and sequence coverage of ECM proteins obtained from ADAMTS16 digestion of BALB/c 3T3 extracellular matrix**

| Protein name | Accession Nr. | Unique peptide count (wtADAMTS16) | Unique peptide count (ADAMTS16-sh) | Unique peptide count (ADAMTS16-sh-EA) | Unique peptide count (vector) | Sequence coverage % (wtADAMTS16) | Sequence coverage % (ADAMTS16-sh) | Sequence coverage % (ADAMTS16-sh-EA) | Sequence coverage % (vector) |
|--------------|---------------|-----------------------------------|------------------------------------|----------------------------------------|-------------------------------|----------------------------------|----------------------------------|------------------------------------|-------------------------------|
| FN           | P11276        | 206                               | 150                                | 186                                    | 180                           | 71                               | 66                               | 70                                 | 72                            |
| LTBP1        | Q8CG19        | 41                                | 27                                 | 21                                     | 25                            | 28                               | 20                               | 17                                 | 21                            |
| POSTN        | Q62009        | 23                                | 23                                 | 25                                     | 23                            | 32                               | 33                               | 37                                 | 30                            |
| GELS         | P13020        | 46                                | 32                                 | 46                                     | 40                            | 57                               | 45                               | 58                                 | 50                            |
| PG51         | P28663        | 5                                  | 8                                  | 10                                     | 12                            | 16                               | 13                               | 30                                 | 39                            |
| SERPH        | P19324        | 3                                  | 4                                  | 12                                     | 14                            | 12                               | 17                               | 39                                 | 39                            |
| PLEC         | Q9QXS1        | 43                                | 23                                 | 14                                     | 11                            | 11                               | 6.4                              | 4.2                               | 3.3                            |

Differences in sequence coverage as well as in peptide counts were obtained for other ECM proteins. Sequence coverage and unique peptide counts were calculated using Scaffold software, the following posttranslational modifications were included in the Mascot search: acetylation at the protein N-terminus, oxidation, phosphorylation and deamidation. No enzyme specificity was applied to the search parameters to identify potential ADAMTS16 cleavage products. All ECM proteins shown in the table are of murine (BALB/c 3T3) origin.

The original scaffold file and the corresponding Mascot search files are available via ProteomeXchange with identifier PXD007284.
binding domain released by wtADAMTS16 was previously shown to regulate FN self-association during fibrillogenesis (5, 6). To investigate whether ADAMTS16 had a direct effect on FN fibril networks, we investigated the temporal effect of ADAMTS16 on the FN network. Human dermal fibroblasts (HDF) co-cultured with HEK cells stably transfected with either vector or inactive ADAMTS16-EA established a robust FN network within 24 h in culture medium containing 10% FBS. In contrast, a profound reduction of FN fibrils was observed in the presence of wtADAMTS16 after 24 h despite comparable cell density (Fig. 3A). Indeed, in the presence of wtADAMTS16, FN was visible as punctate structures localized near the surface of fibroblasts, rather than in a well-defined fibrillar network. Upon continuing co-culture to 2, 4, and 8 days, a similar impact on the network was observed, indicative of a continuing impact on FN assembly, although digestion of preformed fibrils cannot be ruled out (Fig. 3A, 3B, Fig. 4). This temporal sequence in reduction of FN fibrillogenesis suggested that ADAMTS16 affected FN fibril maturation at the point of, or shortly after initial fibril assembly and therefore reduced further assembly and fibril maturation. FN1 mRNA levels were comparable in the various co-cultures (supplemental Fig. S5A), suggesting that reduction of fibrils in the presence of active ADAMTS16 did not have a transcriptional basis. The C-terminally truncated construct, ADAMTS16-sh had a similar effect on fibril maturation as full-length ADAMTS16, showing that the catalytic specificity for FN and inhibition of fibrillogenesis did not rely on the C terminus of the protease (supplemental Fig. S5B, S5C). Moreover, a similar impact was observed on FN networks formed by mouse BALB/c-3T3 fibroblasts, which were used for substrate identification, when co-cultured with wtADAMTS16 expressing HEK-EBNA cells (supplemental Fig. S5D). Impairment of FN assembly in LN-229 cells, HDF and 3T3 cells suggested that the effect of ADAMTS16 was independent of cell type. Because fibrillin-1 (FBN1) and tenascin-C (TN-C) assembly requires a preformed FN network, we used them as reporters for the formation of a stable, mature ECM after formation of the primordial FN matrix. The 8-day co-culture was investigated for proper FBN1 and TN-C assembly, in addition to FN fibrillogenesis. Whereas the ADAMTS16 active-site mutant had no effect on the formation of FBN1 and TN-C fibrils,
active ADAMTS16 strongly impaired the formation of FBN1 and TN-C networks (Fig. 4A, 4B). Whereas collagen IV formed a network with long thin fibers in the presence of ADAMTS16-EA, thicker and shorter collagen IV fibers accumulated in HDF cultures exposed to wtADAMTS16 (Fig. 4C). Therefore, we conclude that ADAMTS16 overexpression can influence the integrity of other ECM assemblies by interference with FN assembly.

**ADAMTS16 Impairs Spheroid Morphogenesis by MDCKI Cells in 3D Collagen Gels Via FN Proteolysis**—Because of prior work indicating a role for ADAMTS16 in renal development (21, 22), renal tubule-derived MDCKI cells, which have very low levels of ADAMTS16 mRNA were used as a model to investigate the effect of ADAMTS16 on tubulogenesis. MDCKI cells stably transfected with ADAMTS16 constructs did not show any obvious morphological differences in monolayer culture (data not shown). When grown in 3-dimensional collagen gels, MDCKI cells form spheroids in which the cells are arranged with strict apical-basal polarity. In this spheroid-formation assay, wtADAMTS16 transfected cells showed less intense FN staining in the basement membrane whereas the ADAMTS16-EA expressing spheroids had stronger FN staining compared with vector control after 4 days and 8 days in 3D culture (Fig. 5A, 5B). This finding suggested increased FN digestion in the presence of ADAMTS16 and that ADAMTS16-EA may stabilize FN fibers in 3D cultures (Fig. 5A, 5B). Therefore, we conclude that ADAMTS16 overexpression reduces spheroid growth and promotes formation of multiluminal spheroids, whereas over-expression of ADAMTS16-EA promotes epithelial-mesenchymal transition in spheroids, evidenced by loss of cell polarity and acquisition of N-cadherin.

**ADAMTS16 Overexpression Up-regulates MMP3 Expression by MDCKI Cells**—Although Western blot analysis of the cell lysate of the MDCKI cells cultured in 2D did not show a significant differences in FN levels between cells expressing different ADAMTS16 constructs (Fig. 5F), the N-terminal 30
Fibronectin Cleavage by ADAMTS16

A vector ADAMTS16-EA ADAMTS16

B vector ADAMTS16-EA ADAMTS16

C vector ADAMTS16-EA ADAMTS16

D vector ADAMTS16-EA ADAMTS16

E vector ADAMTS16-EA ADAMTS16

F vector ADAMTS16-EA ADAMTS16

Molecular & Cellular Proteomics 17.7
kDa FN fragment was evident in the concentrated medium of the wtADAMTS16-expressing cells (Fig. 6A). To ask whether this FN fragment induced MMP3 expression in MDCKI cells, as previously noted in chondrocytes (33), we added it to MDCKI monolayers and quantified MMP3 mRNA expression. We found a significant up-regulation of MMP3 mRNA after 24 h in treated MDCKI cells (Fig. 6B) and MMP3 mRNA levels were also significantly increased in cells expressing wtADAMTS16 for 6 days in 3D cultures (Fig. 6C). Because MMP3 cleaves FN within the (I)_5-(I)_6 linker i.e. generating the 30 kDa fragment similar to ADAMTS16 (34), it is likely that the observed MMP3 mRNA up-regulation leads to a feed-forward loop that may enhance FN proteolysis in MDCKI spheroids.

**DISCUSSION**

Identifying new substrates for proteases is a challenging yet crucial undertaking that is necessary for a better understanding of their function in diverse cellular and disease processes such as development, tissue repair, cancer, and inflammation. Because proteolysis is an irreversible post-translational modification, substrate identification can define pathways that are substantially modified by a protease with lasting consequences. Until now ADAMTS16 has been an orphan protease, i.e. one without known substrates. Although it has been linked to several human diseases, such as cancer and hypertension, its substrates and its mechanism of action were so far unknown. Our data shows that ADAMTS16 is a secreted metalloprotease that acts in a cell-proximate location. After secretion, ADAMTS16 is extensively cleaved within its C-terminal domains such that mature full-length ADAMTS16 is undetectable with antibodies to the C-terminal epitope tags. This results in release of a truncated form of ADAMTS16, which we modeled using the ADAMTS16-sh construct. ADAMTS16-sh had similar activity as ADAMTS16 in the assays utilized, suggesting that the TSR2-PLAC domain is primarily necessary for localizing ADAMTS16 to ECM through yet undetermined interactions, although ADAMTS16-sh clearly also retained some ECM-binding ability.

Here, the use of a cell-free ECM produced in vitro by BALB/c fibroblasts allowed substrate discovery using LC-MS/MS without prior purification of ADAMTS16. This approach is suitable for investigating other ECM-degrading proteases whose purification, like ADAMTS16, is challenging. The ECM used in this approach provided a physiological ECM containing a broad spectrum of potential substrates because fibroblasts typically produce several secreted molecules which are assembled into a well-organized ECM. The mass spectrometry strategy not only identified FN as a potential substrate of ADAMTS16, but also identified a cleavage site in the linker region between repeat (I)_5 and (I)_6 of FN. Release of the 30 kDa N-terminal heparin binding domain, likely affects FN assembly in two ways: FN dimers lacking this region may not assemble properly, and the 30 kDa fragment may interfere with the assembly of intact FN dimers by occupying cell-surface receptors or sites relevant for FN self-assembly (Fig. 6E). The temporal analysis of FN assembly in the presence of wild-type or catalytically inactive ADAMTS16, specifically at an early 24 h time point, suggests that ADAMTS16 primarily interferes with initiation and maturation of FN fibrils. However, release of the 30 kDa FN fragment, as observed by LC-MS/MS after digestion of a pre-formed ECM, indicates that ADAMTS16 is also capable of degrading FN fibrils. The conformation of FN dimers appears to be crucial for regulating proteolytic susceptibility, because ADAMTS16-sh did not cleave soluble plasma FN, which assumes a globular conformation (35) in which the (I)_5-(I)_6 linker region may be concealed. The cryptic site is likely exposed in the presence of cells, which apply tensile forces to FN and FN fibrils upon attachment (36). Other proteases, such as ADAMTS2 and ADAMTS3 (17), have been shown to cleave FN within its (I)_5-(I)_6 linker sequence, indicating its high susceptibility to proteolysis. The findings suggest that there is considerable redundancy in fibronectin processing by proteases. Thus, release of the 30 kDa fragment of FN by proteases is likely to be a widespread mechanism of regulation of FN assembly that has not been extensively studied.

Fig. 5. ADAMTS16 impairs spheroid morphogenesis by MDCKI cells in 3D collagen gels. A, Confocal microscopy of spheroids formed by ADAMTS16-expressing MDCKI cells in 3D collagen gels after 4 days. Spheroids were stained for β-catenin (red), FN (green) and nuclei (DAPI, blue). Quantitative analysis of spheroid diameter in 3D collagen gels shows size reduction upon wtADAMTS16 overexpression compared with vector and ADAMTS16-EA control after 4 days. n = 50 spheroids from 3 independent experiments. (***p < 0.0001, Student t test). B, Confocal microscopy of spheroids formed by ADAMTS16-expressing MDCKI cells in 3D collagen gels after 8 days. Spheroids were stained for FN (red) and nuclei (DAPI, blue). Reduction of FN staining in spheroids expressing wtADAMTS16 was observed whereas spheroids expressing ADAMTS16-EA had increased FN staining. Quantitative analysis of spheroid diameter shows size reduction upon ADAMTS16 overexpression compared with vector and ADAMTS16-EA control after 8 days. n = 50 spheroids from 3 independent experiments. (**p < 0.01, Student t test). C, Spheroids were stained for phalloidin (red) and DAPI (blue) after 8 days in culture. Quantification of lumen formation in spheroids after 8 days in culture. n = 16 per experiment and construct, experiments were repeated 3 times. (*)p < 0.05, (**)p < 0.01, (***)p < 0.001. D, Confocal microscopy of MDCKI spheroids in 3D collagen gels after 8 days showing perturbation of E-cadherin staining in spheroids expressing wtADAMTS16. Spheroids were stained for E-cadherin (green) and nuclei (DAPI, blue). E, Confocal microscopy of spheroids formed by ADAMTS16-expressing MDCKI cells in 3D collagen gels after 8 days. Spheroids were stained for gm130 (red) and nuclei (DAPI, blue). White arrows show polarized gm130 staining. Lower images are 2× amplifications upper panel. F, Western blot analysis of MDCKI cells in monolayer culture. N-cadherin expression was strongly increased in cells expressing ADAMTS16-EA. No changes in E-cadherin or FN levels were observed. Scale bars are 50 μm in A, B and E and 25 μm in C, D. ***, p < 0.01 by student t-test.
Fibronectin Cleavage by ADAMTS16

A

B

C

D

E

F

Molecular & Cellular Proteomics 17.7
The cell-proximate location of ADAMTS16 is relevant because FN assembly is initiated at the cell surface by integrin-binding to secreted dimers (37), and thus FN proteolysis by ADAMTS16 may occur pericellularly. WtADAMTS16 overexpression in MDCKI cells led to a significant reduction in the size of MDCK-derived spheroids associated with reduced FN staining and detection of the 30 kDa FN fragment. Additionally, we observed formation of multiluminal spheroids. These findings are consistent with a previously described reduction of spheroid size and multiple lumen formation in MDCKI cells upon FN knockdown (38, 39), suggesting that the observed impact is a result of reduction of FN in the spheroid ECM. Loss of FN in 3D cultures was also previously linked to loss of cell polarity (40). The 70 kDa N-terminal FN fragment, which blocks FN fibril assembly has been shown to impair angiogenesis in 3D cultures of vascular endothelium in collagen gels (40) and to promote loss of cell polarity during gastrulation (41). Interestingly, spheroids expressing the catalytically inactive ADAMTS16-EA had increased FN accumulation in their basement membrane. Most likely ADAMTS16-EA binds to FN without proteolysis of the protein and acts in a dominant negative manner to prevent other proteases from binding. The resulting accumulation of FN may change matrix stiffness leading to an up-regulation of FN1 expression, which further contributes to the extensive accumulation of FN. Overall these spheroids were larger and failed to form a lumen, in contrast to the vector or wtADAMTS16-expressing spheroids. The cells of ADAMTS16-EA expressing spheroids showed characteristics of epithelial-mesenchymal transition (EMT) upon FN accumulation as shown by the up-regulation of N-Cadherin (Fig. 5F). Previous studies showed that TGFβ overexpression in MDCK cells blocked lumen formation via induction of EMT (42, 43) and that the levels of laminin, fibronectin and collagen IV in the ECM of MDCK spheroids could influence their ability to form a proper lumen (42). FN turnover by ADAMTS16 can therefore potentially influence cell polarity, EMT and morphogenesis in 3D culture systems. The reduction of laminin staining in wtADAMTS16-expressing MDCKI spheroids, taken together with overlapping staining of ADAMTS16 and laminin in HEK293-EBNA cultures, suggests that laminins could also be potential ADAMTS16 substrates; however, BALB/c 3T3 cells produce very low levels of laminin and we did not identify unique laminin peptides in our LC-MS/MS screen.

The 30 kDa N-terminal heparin-binding domain of FN released by ADAMTS16 is not only functionally relevant to FN fibrillogenesis but was previously shown to activate MMP3 expression via integrin signaling in chondrocytes (33). MMP3 and its activation have been extensively studied during branching morphogenesis and cancer (44)(45,46), but little is known about regulation of MMP3 expression by other proteases. Our data showed that the 30 kDa fragment of FN released by ADAMTS16 increased MMP3 expression in MDCKI cells. FN cleavage by MMP3 within the linker region between domain (l), and (l), like ADAMTS16, was previously shown to release the 30 kDa N-terminal heparin binding domain (33, 34). We therefore propose that induction of MMP3 upon ADAMTS16 overexpression creates a feed-forward loop augmenting FN proteolysis (Fig. 6F). Thus, ADAMTS16 and MMP3 might work synergistically in regulation of FN fibril maturation and ECM assembly (Fig. 6F). Although the data suggest that ADAMTS16 cleaves fibronectin directly, i.e. by showing it binds to fibronectin and that purified ADAMTS16 cleaves fibronectin, it is possible that ADAMTS16 may act not only as a terminal protease, but also via activation of an earlier step in a proteolytic pathway, such as by up-regulation of MMP3 or activation of other proteases.

In summary, we have demonstrated that FN turnover by ADAMTS16 has a profound effect on the formation of FN networks and therefore has the potential to modify cell behavior and influence ECM composition and integrity over extended time-scales. Additionally, we have shown that ADAMTS16 drives a feed-forward proteolytic loop, because the N-terminal FN fragment generated increases MMP3 expression in MDCKI cells. Although proteases are typically considered in the context of ECM turnover, the present work supports a major role for ADAMTS16 in regulating ECM assembly. These findings have broad ramifications for proteolysis.
understanding cell behavior and extend the concept of the protease web (47, 48) to illustrate the complexity and interdependence of proteases in discrete cascades and circuits.

Acknowledgments—The authors express their appreciation of the many contributions of the late Ruth Chiquet-Ehrismann (deceased September 4, 2015) to whom this manuscript is dedicated. We thank Prof. Nancy E. Hynes for critical reading of the manuscript and members of the Chiquet-Ehrismann and Apte laboratory for constructive comments. We further thank Dr. Martin Spiess for the MDCK cells and Dr. Jan Seebacher for input on MS analysis.

DATA AVAILABILITY

The authors declare that all data supporting the findings of this study are available within the article and its Supplementary Information files or are available from R.Sc upon request. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (https://www.ebi.ac.uk/pride/archive/) with the dataset identifier PXD007284. Project Webpage: http://www.ebi.ac.uk/pride/archive/projects/PXD007284; FTP Download: ftp://ftp.pride.ebi.ac.uk/pride/archive/data/2018/04/PXD007284; PubMed ID: 29669734.

* This work was supported by grants from: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF, Project funding in biology and medicine (division III)) grant no. 31003A_156740 (to R. C-E), HHS/NIH awards HL107147 and EY024943 (to S.A.), and the Allen Distinguished Investigator Program, and TGF-β signaling as primary targets. FASEB J. 30, 1714–1726.

† Deceased.

** To whom correspondence should be addressed: Department of Biomedical Engineering (ND20), Cleveland Clinic Lerner Research Institute, 9500 Euclid Avenue, Cleveland, OH 44195. Tel.: (216) 445-3278; Fax (216) 444-9198; E-mail: aptes@ccf.org or Friedrich Mescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland. Tel.:+41-61-697-66-51; Fax +41-61-697-397; Email: rahel.schnellmann@fmi.ch.

This article contains supplemental material.

REFERENCES

1. Schwarzbaucer, J. E., and DeSimone, D. W. (2011) Fibronectins, their fibrillogensis, and in vivo functions. Cold Spring Harb. Prospect. Biol. 216, 445–452.

2. Hynes, R. O. (1990) Fibronectins. Cold Spring Harb. Prospect. Biol. 216, 445–452.

3. Grudzenko, T., and Franz, C. M. (2015) Studying early stages of fibronectin fibrillogensis in living cells by atomic force microscopy. Mol. Biol. Cell 26, 3190–3204.

4. Pankov, R., and Yamada, K. M. (2002) Fibronectin at a glance. J. Cell Sci. 115, 3861–3863.

5. Schwarzbaucer, J. E. (1991) Identification of the fibronectin sequences required for assembly of a fibrillar matrix. JCS 113, 1463–1473.

6. McKeown-Longo, P. J., and MOSHERDF. (1985) Interaction of the 70,000-mol-wt Amino-terminal Fragment of Fibronectin with the Matrix-Assembly Receptor of Fibroblasts. J. Cell Biol. 100, 364–374.

7. Sabatier, L., Chen, D., Fagotto-Kaufmann, C., Hubmacher, D., McKee, M. D., Annis, D. S., Mosher, D. F., and Reinhardt, D. P. (2009) Fibrillin assembly requires fibronectin. Mol. Biol. Cell 20, 846–856.

8. Chiquet-Ehrismann, R., Matsuoka, Y., Hoffer, U., Spring, J., Bernasconi, C., and Chiquet, M. (1991) Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul. 11, 927–938.

9. Kubow, K. E., Vukmirovic, R., Zhe, L., Klotzsch, E., Smith, M. L., Gourdon, D., Luna, S., and Vogel, V. (2015) Mechanical forces regulate the interactions of fibronectin and collagen I in extracellular matrix. Nat. Commun. 6, 8026.

10. Dallas, S. L., Silvakumar, P., Jones, C. J., Chen, Q., Peters, D. M., Mosher, D. F., Barlati, S. (1996) Degradation of human plasma and TGF-beta binding protein-1. J. Biol. Chem. 1142, 4039–4050.

11. McKeown-Longo, P. J., and MosherDF. (1985) Interaction of the cell-adhesive domain and an amino-terminal matrix assembly domain participate in its assembly into fibroblast pericellular matrix. J. Biol. Chem. 262, 2957–2967.

12. George, E. L., Georges-Labouesse, E. N., Patel-King, R. S., Rayburn, H., and Apte, S. S. (2014) Targeted disruption of Adamts16 gene in a rat genetic model of hypertension. Proc. Natl. Acad. Sci. U.S.A. 110, 20555–20559.

13. Abdul-Majeed, S., Mell, B., Nauli, S. M., and Joe, B. (2012) Targeted disruption of Adamts16 locus. PLoS ONE 9, e100967.

14. Jakobi, C. L., Rudigier, L. J., Scholz, H., and Kirschner, K. M. (2013) Transcriptional regulation by the Wilms tumor protein, WT1, suggests a role of the metalloproteinase Adamts16 in murine genitourinary development. J. Biol. Chem. 288, 18811–18824.

15. Gopalakrishnan, K., Kumasayama, S., Abdul-Majeed, S., Kalinoski, A. L., Morgan, E. E., Gohara, A. F., Nauli, S. M., Filipiak, W. E., Saunders, T. L., and Joe, B. (2012) Targeted disruption of Adamts16 gene in a rat genetic model of hypertension. Proc. Natl. Acad. Sci. U.S.A. 109, 20555–20559.

16. McKeown-Longo, P. J., and MosherDF. (1985) Interaction of the cell-adhesive domain and an amino-terminal matrix assembly domain participate in its assembly into fibroblast pericellular matrix. J. Biol. Chem. 262, 2957–2967.
site-directed and site-saturation mutagenesis protocol. Nucleic Acids Res. 32, e115

27. Beacham, D. A., Amatangelo, M. D., and Cukierman, E. (2007) Preparation of Extracellular Matrices Produced by Cultured and Primary Fibroblasts. Curr. Protoc. Cell Biol., 10.19.11–10.19.21

28. Asparuhova, M. B., Ferralli, J., Chiquet, M., and Chiquet-Ehrismann, R. (2011) The transcriptional regulator megakaryoblastic leukemia-1 mediates serum response factor-independent activation of tenascin-C transcription by mechanical stress. FASEB J. 25, 3477–3488

29. Schmittgen, T. D., and Livak, K. J. (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108

30. Maurer, L. M., Tomasini-Johansson, B. R., Ma, W., Annis, D. S., Eickstaedt, N. L., Ensenberger, M. G., Satyshur, K. A., and Mosher, D. F. (2010) Extended Binding Site on Fibronectin for the Functional Upstream Domain of Protein F1 of Streptococcus pyogenes. J. Biol. Chem. 285, 41087–41099

31. Cal, S., Obaya, A. J., Llamazares, M., Garabaya, C., Quesada, V., and López-Otín, C. (2002) Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283, 49–62

32. Gao, S., Geyter, C. D., Kossowska, K., and Zhang, H. (2007) FSH stimulates the expression of the ADAMTS-16 protease in mature human ovarian follicles. Mol. Hum. Reprod. 13, 465–471

33. Ding, L., Guo, D., and Homandberg, G. A. (2008) The cartilage chondrolytic mechanism of fibronectin fragments involves MAP kinases: comparison of three fragments and native fibronectin. Osteoarthritis Cartilage 16, 1253–1262

34. Muir, D., and Manthorpe, M. (1992) Stromelysin generates a fibronectin fragment that inhibits Schwann cell proliferation. J. Cell Biol. 116, 177–185

35. Maurer, L. M., Ma, W., and Mosher, D. F. (2016) Dynamic structure of plasma fibronectin. Crit. Rev. Biochem. Mol. Biol. 51, 213–227

36. Siwakumar, P., Czirok, A., Rongish, B. J., Divakara, V. P., Wang, Y. P., and Dallas, S. L. (2006) New insights into extracellular matrix assembly and reorganization from dynamic imaging of extracellular matrix proteins in living osteoblasts. J. Cell Sci. 119, 1350–1360

37. Sechler, J. L., Corbett, S. A., and Schwarzbauer, J. E. (1997) Modulatory roles for integrin activation and the synergy site of fibronectin during matrix assembly. Mol. Biol. Cell 8, 2563–2573

38. Jiang, S. T., Chiang, H. C., Cheng, M. H., Yang, T. P., Chuang, W. J., and Tang, M. J. (1999) Role of fibronectin deposition in cystogenesis of Madin-Darby canine kidney cells. Kidney Int. 56, 92–103

39. Jiang, S. T., Chuang, W. J., and Tang, M. J. (2000) Role of fibronectin deposition in branching morphogenesis of Madin-Darby canine kidney cells. Kidney Int. 57, 1860–1867

40. Zhou, X., Rowe, R. G., Hiraoka, N., George, J. P., Wirtz, D., Mosher, D. F., Virtanen, I., Chernousov, M. A., and Weiss, S. J. (2008) Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. Genes Dev. 22, 1231–1243

41. Rozario, T., Dzamba, B., Weber, G. F., Davidson, L. A., and DeSimone, D. W. (2009) The physical state of fibronectin matrix differentially regulates morphogenetic movements in vivo. Dev. Biol. 327, 386–398

42. Santos, O. F., and Nigam, S. K. (1993) HGF-induced tubulogenesis and branching of epithelial cells is modulated by extracellular matrix and TGF-beta. Dev. Biol. 16, 293–302

43. Sakurai, H., and Nigam, S. K. (1997) Transforming growth factor-beta selectively inhibits branching morphogenesis but not tubulogenesis. Am. J. Physiol. 272, 139–146

44. Talhouk, R. S., Chin, J. R., Unemori, E. N., Werb, Z., and Bissell, M. J. (1991) Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development 112, 439–449

45. Nagase, H., Enghild, J. J., Suzuki, K., and Salvesen, G. (1990) Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 29, 5783–5789

46. Overall, C. M., and Kleifeld, O. (2006) Tumour microenvironment—opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227–239

47. Keller Ua., Doucet, A., and CMO. (2007) Protease research in the era of systems biology. Biol. Chem. 386, 1159–1162

48. Fortelny, N., Cox, J. H., Kappelhoff, R., Starr, A. E., Lange, P. F., Pavlidis, P., and Overall, C. M. (2014) Network analyses reveal pervasive functional regulation between proteases in the human protease web. PLoS Biol. 12, e1001869